Product Description: BGT226 (NVP-BGT226) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ)/mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells[1][2].
Applications: Cancer-Kinase/protease
Formula: C28H25F3N6O2
Citations: Molecules. 2020 Apr 23;25(8):1980./Arch Pharm (Weinheim). 2024 Sep;357(9):e2400066./Front Pharmacol. 2020 Nov 11;11:580407./Harvard Medical School LINCS LIBRARY/Research Square Print. 2023 Mar 9./Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
References: [1]Markman B, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol. 2012 Sep;23(9):2399-408./[2]Chang KY, et al. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clin Cancer Res. 2011 Nov 15;17(22):7116-26.
CAS Number: 915020-55-2
Molecular Weight: 534.53
Compound Purity: 99.51
Research Area: Cancer
Solubility: DMSO : 10 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Autophagy;mTOR;PI3K
Deutsch
English
